Abstract: A cranial anchor system configured to attach to an opening in a cranium includes an anchor member. The anchor member has a middle anchor portion and a lower anchor portion coupled to and disposed in a downward direction relative to the middle anchor portion. The lower anchor portion has a plurality of contact members, each of which have a leg that extends at least partially in the downward direction, a tab connected to the leg, and a rib disposed between the leg and the tab. The system further includes an outer sheath and an inner sheath disposed within the outer sheath and slidable relative to the outer sheath.

Abstract: Isolated or recombinant monoclonal antibodies that bind to GARP are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. Further provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of an anti-platelet agent and a T cell therapy.

Abstract: A declogging assembly (20) is configured for use with a suction conduit (10). The suction conduit has a head (14) at a first end (15) and a vacuum tube connection (16) at a second end (17). The assembly includes a body (30). The body defines a first aperture (32), a second aperture (34), and a third aperture (36). The assembly also includes a plug (40) disposed within the body (30). The plug has a surface (42) configured to contact the head (14) of the suction conduit (10) so as to move the plug from a first position, in which the first aperture (32) is in fluid communication with the second aperture (34), to a second position, in which the first aperture (32) is in fluid communication with the third aperture (36). The assembly (20) also includes a biasing member (50) configured to bias the plug into the first position.

Abstract: The present invention provides minimally invasive subdural evacuating systems and methods of use thereof. The subdural evacuating systems include a cutting component and a rod component, wherein the rod component provides an external physical indicator that the surface of the dura mater has been reached, permitting the cutting component to accurately pierce the dura mater with minimal to no risk of damaging any adjacent anatomy.

Abstract: The present disclosure provides a recombinant oncolytic virus engineered to express a soluble form of an immune checkpoint protein. In certain aspects, the oncolytic vims is a replication competent virus such as myxoma vims. Methods of cancer treatment comprising administering the recombinant oncolytic virus expressing the soluble form of the immune checkpoint protein are also provided.

Abstract: Isolated or recombinant monoclonal antibodies that bind to GARP are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. Further provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of an anti-platelet agent and a T cell therapy.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, promote mitochondrial biogenesis and are useful for the treatment of, for example, acute kidney injury and chronic kidney disease.

Abstract: The present invention describes compositions and method for improving outcomes after injury to the central nervous system wherein complement signaling is activated. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a therapeutic agent comprising a targeted inhibitor molecule comprising a targeting portion and an inhibitor portion, wherein the molecule inhibits complement, and wherein therapeutic agent is administered in combination with rehabilitation therapy or thrombolytic agent.

Abstract: The present invention provides expandable devices and insertion tools for deploying the expandable devices. The expandable devices are capable of increasing in height and width when expanded from a closed configuration to an open configuration to occupy a larger volume and to present a larger surface area. The expandable devices are lockable and are capable of rigidly occupying a space after expansion. In some embodiments, the expandable devices are useful as interbody devices for spinal fusions.

Abstract: Described herein are tissues containing semiconductor nanomaterials. In some embodiments, the tissues include vascular cells, cardiomyocytes, and/or cardiac fibroblasts. The tissue may be scaffold-free. In some embodiments, the tissue includes an electrically conductive network. The tissue may exhibit synchronized electrical signal propagation within the tissue. In some embodiments, the tissue exhibits increased functional assembly of cardiac cells and/or increased cardiac specific functions compared to a cardiac tissue prepared using a conventional tissue culture method. Methods of preparing and using such tissues are also described herein.

Abstract: Provided herein are methods of inhibiting GARP cleavage, such as by administering a GARP peptide or a direct thrombin inhibitor. Further provided herein are methods of treating cancer by inhibiting GARP cleavage as well as methods of identifying subjects with platelet activation who would benefit from inhibition of GARP cleavage.

Abstract: A needle electrode fixation device is configured to secure a transdermal needle electrode to a patient. The device includes a base having a body that defines a first portion and a second portion. The first and second portions are rotatable relative to each other. The first portion defines a channel configured to fit a portion of the transdermal needle electrode. The second portion defines a recess configured to fit a tip of the needle electrode. The device further includes an adhesive layer configured to affix the base to the patient.

Abstract: The present disclosure provides methods for the treatment of neurological deficits by the administration of GSNO or GSNO reductase inhibitor. Further provided herein are methods of treating autoimmune diseases by administering GSNO or GSNO reductase inhibitor.

Abstract: Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of cancer.

Abstract: The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.

Abstract: This document provides materials and methods for producing endostatin fusion polypeptides having anti-fibrotic activity. For example, provided herein are fusion polypeptides having an IgG Fc domain and a portion of human endostatin that can form high molecular weight multimers, as well as methods for producing such fusion polypeptides in plant cells.

Abstract: A skeletal fixation apparatus may include two or more bodies that are attached to two or more screws that have been inserted into vertebral bodies associated with a patient. The apparatus may also include two or more cylindrical members that are attached to the bodies to control the movement or alignment of the bodies when the skeletal fixation apparatus is being installed in the patient. The apparatus may further include a rod that includes a first curvature and a second curvature. The first curvature may be different than the second curvature and may be based on a medical diagnosis associated with stabilizing the vertebral bodies. The second curvature may enable the bodies to be immovably fastened to the rod in a manner that precludes the cylindrical members from contacting each other or causing a false torque condition to exist when the skeletal fixation apparatus is installed in the patient.

Abstract: Provided herein are methods for the production of enhanced ICOS-stimulated Th17 cells by co-stimulation with inducible coactivator (ICOS) and an inhibitor of POK/Akt signaling and/or an inhibitor of Wnt/?-catenin signaling. Further provided are methods for treatment of cancer by administration of the enhanced ICOS-stimulated Th17 cells as an adoptive T cell therapy.